Mannan binding lectin as an adjunct to risk assessment for myocardial infarction in individuals with enhanced risk.
about
Mannose-binding lectin: biology and clinical implicationsFluorochrome-linked immunoassay for functional analysis of the mannose binding lectin complement pathway to the level of C3 cleavage.Deficiency of complement factor MBL in a patient required cardiac surgery after an acute myocardial infarction with underlining chronic lymphocytic leukemia.Genetic and other factors determining mannose-binding lectin levels in American Indians: the Strong Heart Study.Mannan-binding lectin in cardiovascular disease.Mannose-binding lectin genotype and phenotype in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.The MBL2 'LYQA secretor' haplotype is an independent predictor of postoperative myocardial infarction in whites undergoing coronary artery bypass graft surgery.Mannose-binding lectin in innate immunity: past, present and future.New insights of an old defense system: structure, function, and clinical relevance of the complement system.The lectin pathway of complement and rheumatic heart disease.Mannan Binding Lectin (MBL) genotypes coding for high MBL serum levels are associated with rheumatoid factor negative rheumatoid arthritis in never smokersLow Mannose-Binding Lectin (MBL) genotype is associated with future cardiovascular events in type 2 diabetic South Asians. A prospective cohort studyMannan-binding lectin and complement C4A in Icelandic multicase families with systemic lupus erythematosusMASP-2 activation is involved in ischemia-related necrotic myocardial injury in humansInnate immune proteins C1q and mannan-binding lectin enhance clearance of atherogenic lipoproteins by human monocytes and macrophagesHigh rate of in-stent restenosis after coronary intervention in carriers of the mutant mannose-binding lectin allele.Mannose-Binding Lectin Levels and Carotid Intima-Media Thickness in Type 2 Diabetic PatientsAtherogenesis in rheumatology.Natural antibodies, autoantibodies and complement activation in tissue injury.Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients.Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics.Mannose-binding lectin 2 (Mbl2) gene polymorphisms are related to protein plasma levels, but not to heart disease and infection by Chlamydia.Lectin Pathway of Complement Activation Is Associated with Vulnerability of Atherosclerotic PlaquesComplement in atherosclerosis: friend or foe?Mannose-binding lectin as a risk factor for acute coronary syndromes.Molecular biology of atherosclerosis.Mannose-binding lectin without the aid of its associated serine proteases alters lipopolysaccharide-mediated cytokine/chemokine secretion from human endothelial cells.Hormonal regulation of mannan-binding lectin synthesis in hepatocytes.Association of Low Ficolin-Lectin Pathway Parameters with Cardiac Syndrome X.Serum levels and H/L gene polymorphism of mannose-binding lectin in primary open angle glaucoma.
P2860
Q28267664-D49427FD-FF59-4A8F-BAD2-A5CB5F512179Q30441472-2B41042B-172A-4F14-A68D-67D05E31962BQ30470544-94DB0310-863B-4946-B4C0-28A0445E1D53Q33401966-4358279F-6170-438C-BEF6-32DD5835891BQ33616097-97C0E84D-F170-4F77-A734-3EC61D0911CBQ34237480-2EC33E7D-5B3B-4F29-9A7A-B8A7604CC1C8Q34400153-29F1DDF3-E105-4809-811B-144F02DEAC48Q34562723-147F332C-F585-4197-A781-A8A271EC156AQ34699496-2D60ED60-C651-42FB-BEAD-B70791E39DE3Q34991781-A5F6D9EC-E6F0-4385-99EF-B335DED0E6C4Q35093031-5EAFB09B-48B1-4493-A5CE-78F79766780DQ35168656-864591BD-84C8-4B88-BBC5-42CC5C52A76EQ35638080-677A19FE-3A06-4DE3-B6F2-C2AF3093E3D2Q35848395-5415F778-489E-478E-B52F-0CA0482787D7Q35906619-F9F92540-38AF-417F-925E-732C5B68FE6BQ36240744-C7204E1A-327C-4D9F-97D1-8117537E8F82Q36310396-781E9480-A19A-45EE-AECD-B7CE50C893ABQ36458127-7B7F583E-4088-4E1E-9CE9-8183EAE6E9D4Q36572982-FCB3B74D-8F3C-45A8-848C-985CA82794E6Q37090971-559FB11E-CF30-45D0-8CBC-D3D7F2732D86Q37154054-2474B5E9-0ECE-42FC-ABD5-AFBF7CCEF1FAQ37297554-EFA566A5-45E1-45D4-ADE8-9BAFD757A701Q37535679-EA72E45C-C767-4B25-9A12-A4C6AF60B65CQ37703122-186FFA3F-FC12-4A62-83FF-A8E21FA78F51Q37820714-1C6A4D2D-7DF8-46BD-AF84-DA57C764E116Q37854397-6B9DA0C5-3256-4623-892E-F0154F27782CQ38125279-6995DBBA-BFC6-4DF7-AA27-A447C7BDCBB5Q38505801-36BC0EE4-4B8B-405F-B437-B40067C22411Q40263955-0C3E3AC2-B3A5-4C52-8681-B819646E872BQ51699092-6D0683A0-094F-4B84-9D5A-7174EA854CB9Q54324076-C682240B-677F-49DF-BC2C-22D652C31E52
P2860
Mannan binding lectin as an adjunct to risk assessment for myocardial infarction in individuals with enhanced risk.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Mannan binding lectin as an ad ...... ndividuals with enhanced risk.
@ast
Mannan binding lectin as an ad ...... ndividuals with enhanced risk.
@en
type
label
Mannan binding lectin as an ad ...... ndividuals with enhanced risk.
@ast
Mannan binding lectin as an ad ...... ndividuals with enhanced risk.
@en
prefLabel
Mannan binding lectin as an ad ...... ndividuals with enhanced risk.
@ast
Mannan binding lectin as an ad ...... ndividuals with enhanced risk.
@en
P2093
P2860
P50
P356
P1476
Mannan binding lectin as an ad ...... ndividuals with enhanced risk.
@en
P2093
Helgi Valdimarsson
Oskar Orn Oskarsson
Saedis Saevarsdottir
Thora Vikingsdottir
P2860
P304
P356
10.1084/JEM.20041431
P407
P577
2004-12-28T00:00:00Z